Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apabetalone in Hospitalized COVID-19 Patients
NCT04894266Phase 3Terminated
- Sponsor
- Resverlogix Corp.
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apabetalone in coronavirus disease 2019 (COVID-19), sponsored by Resverlogix Corp.. Started Jan 2022; status: terminated.
02
Drugs
apabetalone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04894266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894266.